Xcellerate Patient Intelligence provides actual patient feedback from over 30 countries across 50 indications that can be used to help design protocols that reduce the burden on patients and caregivers.
Cost is a major factor in executing a clinical trial. Sponsors are continually seeking ways to reduce their financial risk in early Phase I and human absorption, metabolism and excretion (hAME) studies. Beginning a full CMC campaign only to have to cancel it or change formulation based on late toxicology results or safety data can add expensive delays.
Learn from three thought leaders in the field of immunotherapy as they share their knowledge on trends and advances across the entire spectrum of development.
The COVID-19 pandemic has brought unprecedented challenges in clinical development. Travel restrictions, social distancing and the fear of contracting the disease are impeding conventional trial conduct.
As drug development sponsors are incorporating patient-centric elements into their traditional clinical trial designs, there are several factors to consider during the study planning phase.
The impact that external events like the COVID-19 pandemic can have on clinical trials, as well as a company's entire drug development portfolio, can be far reaching. Tracking metrics associated with these crises is essential to enable study teams to follow global trends of the impact.
